Sagimet Biosciences GAAP EPS of -$0.50 beats by $0.13

Sagimet Biosciences press release ( NASDAQ: SGMT ): Q4 GAAP EPS of -$0.50 beats by $0.13 .

Cash, cash equivalents and marketable securities as of December 31, 2024, was $158.7 million, which are expected to fund operations for at least the next 12 months from the issuance of the financial statements for the year ended December 31, 2024. More on Sagimet Biosciences Sagimet Biosciences' Denifanstat Should Be Worth More Today Seeking Alpha’s Quant Rating on Sagimet Biosciences Historical earnings data for Sagimet Biosciences Financial information for Sagimet Biosciences.